Back
 OJD  Vol.9 No.2 , May 2020
Detection and Evaluation of Adverse Drug Reaction Signals of Antidepressants Based on FDA Adverse Event Reporting System Database
Abstract: Background: Pre-marketing clinical research of drugs can not completely solve the safety problems in the process of wide application of drugs post-marketing, so it is necessary to re-evaluate the safety and effectiveness of drugs after marketing. Objective: To detect and analyze the adverse drug reaction (ADR) signals of Selective Serotonin Reuptake Inhibitor (SSRIs) post-marketing and provide references for clinical rational drug use. Methods: Reporting Ratio (ROR) method was used to mine the adverse reaction signals of SSRIs in the Adverse Reaction Reporting System (ARES) of the Food and Drug Administration of the United States (FDA), and the results were analyzed and evaluated. Results: Adverse Drug Events (ADEs) of fluoxetine, fluvoxamine, paroxetine, sertraline and citalopram were 40,217, 2907, 52,439, 63,849 and 42,588 cases respectively. After ROR test, there were 187 ADR signals of the five drugs, among which ADR was most prominent in psychiatric and nervous system. It mainly includes adverse reactions such as anxiety, depression, suicidal ideation, 5-HT syndrome, withdrawal syndrome and so on. Conclusion: The study based on ADR signals in the real world is helpful to evaluate the post-marking safety drugs and provide references for safety in clinical medication.
Cite this paper: Ran, C. , Zhou, H. , Tan, C. , Tan, J. , Zhang, Z. and Zhao, W. (2020) Detection and Evaluation of Adverse Drug Reaction Signals of Antidepressants Based on FDA Adverse Event Reporting System Database. Open Journal of Depression, 9, 17-25. doi: 10.4236/ojd.2020.92002.
References

[1]   Böhm, R., Von Hehn, L., Herdegen, T. et al. (2016). OpenVigil FDA—Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications. Plos One, 11, e157753.
https://doi.org/10.1371/journal.pone.0157753

[2]   Friedman, R. A., & Leon, A. C. (2007). Expanding the Black Box—Depression, Antidepressants, and the Risk of Suicide. New England Journal of Medicine, 356, 2343.
https://doi.org/10.1056/NEJMp078015

[3]   Hammad, T. A., Laughren, T., & Racoosin, J. (2006). Suicidality in Pediatric Patients Treated with Antidepressant Drugs. Archives of General Psychiatry, 63, 332-339.
https://doi.org/10.1001/archpsyc.63.3.332

[4]   He, Z. Y., Zhu, W., & Wu, S. (2018). Effect of Selective Serotonin Reuptake Inhibitors on Cognitive Function in Adolescent Patients with Depression. China Pharmaceuticals, 27, 43-46.

[5]   Leon, A. C. (2007). The Revised Warning for Antidepressants and Suicidality: Unveiling the Black Box of Statistical Analyses. American Journal of Psychiatry, 164, 1786-1789.
https://doi.org/10.1176/appi.ajp.2007.07050775

[6]   Luo, L., Li, Q. L., & Liu, J. G. (2008). Overview of Researches on Safety of Selective Serotion Inreuptake Inhibitors. Adverse Drug Reactions Journal, 10, 412-417.

[7]   Nardi, B., Francesconi, G., Catenadell’Osso, M. et al. (2013). Adolescent Depression: Clinical Features and Therapeutic Strategies. European Review for Medical & Pharmacological Sciences, 17, 1546-1551.

[8]   Ng, W., Kennar, R., & Uetrecht, J. (2014). Effect of Clozapine and Olanzapine on Neutrophil Kinetics: Implications for Drug-Induced Agranulocytosis. Chemical Research in Toxicology, 27, 1104-1108.
https://doi.org/10.1021/tx500183x

[9]   Radovic, A., Farris, C., Reynolds, K. et al. (2014). Primary Care Providers’ Initial Treatment Decisions and Antidepressant Prescribing for Adolescent Depression. Journal of Developmental & Behavioral Pediatrics, 35, 28-37.
https://doi.org/10.1097/DBP.0000000000000008

[10]   Rothman, K. J., Lanes, S., & Sacks, S. T. (2004). The Reporting Odds Ratio and Its Advantages over the Proportional Reporting Ratio. Pharmacoepidemiology & Drug Safety, 13, 519-523.
https://doi.org/10.1002/pds.1001

[11]   Spindelegger, C. J., Papageorgiou, K., Grohmann, R. et al. (2015). Cardiovascular Adverse Reactions during Antidepressant Treatment: A Drug Surveillance Report of German-Speaking Countries between 1993 and 2010. International Journal of Neuropsychopharmacology, 18, u80.
https://doi.org/10.1093/ijnp/pyu080

[12]   Wang, C. Y. (2011). Brief Description of Weight Gain Effect of Antidepressants. Sichuan Mental Health, 24, 125-126.

[13]   Wong, C. K., Ho, S. S., Saini, B. et al. (2015). Standardisation of the FAERS Database: A Systematic Approach to Manually Recoding Drug Name Variants. Pharmacoepidemiology & Drug Safety, 24, 731-737.
https://doi.org/10.1002/pds.3805

[14]   Yu, Y. (2016). Adverse Drug Reaction Knowledge Integration and Application Research Based on Big Data Mining. Jilin: Jilin University.

[15]   Zhou, M., Chen, M., & Xu, Y. (2010). Retrospective Analysis of Adverse Reactions of Selective Serotonin Reuptake Inhibitors. Chinese Journal of Hospital Pharmacy, 30, 619-620.

[16]   Zhu, J. F. (2018). Adverse Reactions of Antidepressants. Herald of Medicine, 10, 1198-1202.

 
 
Top